Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Psoriasis
Interventions
DRUG

Calcipotriene 0.005% Foam

All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).

Trial Locations (36)

10467

Investigational Site, New York

17033

Investigational Site, Hershey

19109

Philadelphia

23502

Investigational Site, Norfolk

27157

Investigational Site, Winston-Salem

27516

Investigational Site, Chapel Hill

30022

Investigational Site, Alpharetta

30060

Investigational Site, Marietta

30328

Investigational Site, Sandy Springs

30342

Atlanta

32204

Investigational Site, Jacksonville

33014

Miami

33021

Investigational Site, Hollywood

33136

Investigational Site, Miami

33690

Investigational Site, Tampa

35233

Investigational Site, Birmingham

46188

Investigational Site, Plainfield

48334

Investigational Site, Farmington Hills

60614

Investigational Site, Chicago

63104

Investigational Site, St Louis

63117

Investigational Site, St Louis

64506

Saint Joseph

72758

Investigational Site, Rogers

77030

Investigational Site, Houston

77056

Investigational Site, Houston

78218

San Antonio

78723

Investigational Site, Austin

91403

Sherman Oaks

91436

Investigational Site, Encino

92705

Santa Ana

92708

Fountain Valley

97239

Investigational Site, Portland

98418

Investigational Site, Tacoma

99202

Investigational Site, Spokane

02135

Brighton

84132-2409

Investigational Site, Salt Lake City

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Mayne Pharma International Pty Ltd

INDUSTRY